Orchard Therapeutics PLC
Su Syonmez has a strong background in pharmacovigilance, holding roles at various pharmaceutical companies such as Orchard Therapeutics, Eli Lilly and Company, and AstraZeneca. Beginning as an intern at MSD Turkey and Sandoz, Su progressed to roles of increasing responsibility, including Pharmacovigilance Specialist at Eli Lilly and Company and Senior Scientist in Pharmacovigilance at Orchard Therapeutics. They have extensive experience in managing safety activities, contributing to regulatory agency submissions, and providing support and training to team members.
Su Syonmez completed their Bachelor's Degree in Pharmacy at Yeditepe University from 2009 to 2014. Su then pursued a Master of Science (MSc) in Pharmacogenetics and Stratified Medicine at UCL from 2014 to 2015. Prior to their higher education, Su Syonmez attended Galatasaray Lisesi from 2005 to 2009. Additionally, they obtained various certifications related to their field, including courses on gene therapy, clinical trials, lab techniques, and pharmacogenomics.
This person is not in any offices
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.